A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

CDK inhibitors: positive and negative regulators of G1-phase progression

Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · see citing works

The Biology of Vascular Endothelial Growth Factor

Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,540 · see citing works

Vascular endothelial growth factor (VEGF) and its receptors

Neufeld, G., Cohen, T., Gengrinovitch, S., & Gluzman‐Poltorak, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,488 · see citing works

Aging, Cellular Senescence, and Cancer

Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 1× · see citing works

RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement

Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,651 · see citing works

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742 · see citing works

Role of the INK4a Locus in Tumor Suppression and Cell Mortality

Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · see citing works

To cycle or not to cycle: a critical decision in cancer

Malumbres, M., & Barbacid, M. (2001) · Nature reviews. Cancer · doi:10.1038/35106065 · Cited by 1,475 · see citing works

Cyclin D as a therapeutic target in cancer

Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · see citing works

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1× · see citing works

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · see citing works

A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann, E., Plaen, E. D., Hankeln, T., Büschenfelde, K. M. Z., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,153 · see citing works

D-Type Cyclin-Dependent Kinase Activity in Mammalian Cells

Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., & Kato, J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2066 · Cited by 1,067 · see citing works

The p16INK4a/CDKN2A tumor suppressor and its relatives

Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911 · see citing works

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793 · see citing works

Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and cip and INK4 inhibitors

Pavletich, N. P. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2640 · Cited by 746 · see citing works

The retinoblastoma tumour suppressor in development and cancer

Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738 · see citing works

Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle

Ekholm, S. V., & Reed, S. I. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00151-4 · Cited by 587 · see citing works

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543 · see citing works

Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.

Cordon‐Cardo, C. (1995) · PubMed Central · Cited by 532 · see citing works

Cyclins and cdks in development and cancer: a perspective

Deshpande, A., Siciński, P., & Hinds, P. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208618 · Cited by 467 · see citing works

Cell-cycle inhibitors: three families united by a common cause

Vidal, A., & Koff, A. (2000) · Gene · doi:10.1016/s0378-1119(00)00092-5 · Cited by 429 · see citing works

The H3K27me3 demethylase JMJD3 contributes to the activation of the<i>INK4A–ARF</i>locus in response to oncogene- and stress-induced senescence

Agger, K., Cloos, P. A. C., Rudkjær, L., Williams, K., Andersen, G., Christensen, J., & Helin, K. (2009) · Genes &amp; Development · doi:10.1101/gad.510809 · Cited by 427 · see citing works

High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL

Goldstein, A. M., Chan, M., Harland, M., Gillanders, E. M., Hayward, N. K., Avril, M.-F., Azizi, E., Bianchi-Scarra, G., Bishop, D. T., Bressac-de Paillerets, B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0494 · Cited by 426 · see citing works

Nuclear cyclin D1: an oncogenic driver in human cancer

Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413 · see citing works

Histone demethylase JMJD3 contributes to epigenetic control of <i>INK4a/ARF</i> by oncogenic RAS

Barradas, M., Anderton, E., Acosta, J. C., Li, S., Banito, A., Rodriguez-Niedenführ, M., Maertens, G., Banck, M., Zhou, M.-M., Walsh, M. J., et al. (2009) · Genes &amp; Development · doi:10.1101/gad.511109 · Cited by 352 · see citing works

The Requirement for Cyclin D Function in Tumor Maintenance

Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342 · see citing works

microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma

Zhao, J., Lin, J., Lwin, T., Yang, H., Guo, J., Kong, W. W., Dessureault, S., Moscinski, L. C., Rezania, D., Dalton, W. S., et al. (2010) · Blood · doi:10.1182/blood-2009-09-243147 · Cited by 336 · see citing works

JunB suppresses cell proliferation by transcriptional activation of p16INK4a expression

Passegue, E. A., & Wagner, E. F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2969 · Cited by 333 · see citing works

A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers

Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., et al. (2011) · Nature · doi:10.1038/nature10155 · Cited by 333 · see citing works

Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis

Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329 · see citing works

D-Type Cyclin-Dependent Kinase Activity in Mammalian Cells

Matsushime, H., Quelle, D. E., Shurtleff, S. A., et al. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2066-2076.1994 · Cited by 324 · see citing works

INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions

Cánepa, E. T., Scassa, M. É., Ceruti, J. M., Marazita, M. C., Carcagno, A. L., Sirkin, P. F., & Ogara, M. F. (2007) · IUBMB Life · doi:10.1080/15216540701488358 · Cited by 314 · see citing works

Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia

Agirre, X., Vilas‐Zornoza, A., Jiménez‐Velasco, A., Martín-Subero, J. I., Cordeu, L., Gárate, L., José‐Eneriz, E. S., Abizanda, G., Rodríguez‐Otero, P., Fortes, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4025 · Cited by 302 · see citing works

Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias [see comments]

Hebert, J., Cayuela, J., Berkeley, J. L., & Sigaux, F. (1994) · Blood · doi:10.1182/blood.v84.12.4038.bloodjournal84124038 · Cited by 281 · see citing works

Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen

Bienvenu, F., Jirawatnotai, S., Elias, J. E., Meyer, C. A., Mizeracka, K., Marson, A., Frampton, G. M., Cole, M. F., Odom, D. T., Odajima, J., et al. (2010) · Nature · doi:10.1038/nature08684 · Cited by 276 · see citing works

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors

Chiarle, R., Gong, J. Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., Simmons, W. J., Dhall, G., Howes, J. E., Piva, R., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1343 · Cited by 250 · see citing works

Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies

Wong, K. Y., So, C. C., Loong, F., Chung, L.-P., Lam, W. W. L., Liang, R. H. S., Li, G. K. H., Jin, D., & Chim, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019027 · Cited by 247 · see citing works

The CDK inhibitors in cancer research and therapy

Cicenas, J., & Valius, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1039-4 · Cited by 244 · see citing works

Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas

Mao, X., Orchard, G. E., Lillington, D. M., Russell‐Jones, R., Young, B. D., & Whittaker, S. J. (2003) · Blood · doi:10.1182/blood-2002-08-2434 · Cited by 193 · see citing works

Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia

Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183 · see citing works

Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development

Schwartz, R., Engel, I., Fallahi‐Sichani, M., Petrie, H. T., & Murre, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603728103 · Cited by 144 · see citing works

Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescencePreprint

Zou, X., Ray, D., Aziyu, A., Christov, K. T., Boiko, A. D., Gudkov, A. V., & Kiyokawa, H. (2002) · Genes & Development · doi:10.1101/gad.1033002 · Cited by 143 · see citing works

Critical role for NF‐κB‐induced JunB in VEGF regulation and tumor angiogenesis

Schmidt, D., Textor, B., Pein, O. T., Licht, A. H., Andrecht, S., Sator‐Schmitt, M., Fusenig, N. E., Angel, P. E., & Schorpp‐Kistner, M. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601539 · Cited by 139 · see citing works

Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response

Li, Z., Jiao, X., Wang, C., Shirley, L. A., Elsaleh, H., Dahl, O., Wang, M., Soutoglou, E., Knudsen, E. S., & Pestell, R. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0312 · Cited by 124 · see citing works

Cell Cycle Progression without Cyclin D-CDK4 and Cyclin D-CDK6 Complexes

Kozar, K., & Siciński, P. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1551 · Cited by 123 · see citing works

A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis

Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 116 · see citing works

Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis

Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 105 · see citing works

Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features

Fizzotti, M., Cimino, G. G., Pisegna, S., Alimena, G., Quartarone, C., Mandelli, F., Pelicci, P. G., & Coco, F. L. (1995) · Blood · doi:10.1182/blood.v85.10.2685.bloodjournal85102685 · Cited by 104 · see citing works

Homozygous Deletion of the p16/MTS1 Gene in Pediatric Acute Lymphoblastic Leukemia Is Associated With Unfavorable Clinical Outcome

Kees, U. R., Burton, P. R., Lü, C., & Baker, D. L. (1997) · Blood · doi:10.1182/blood.v89.11.4161 · Cited by 103 · see citing works

JunB gene expression is inactivated by methylation in chronic myeloid leukemia

Yang, M., Liu, T., Chang, J., Lin, P., & Lin, S. (2003) · Blood · doi:10.1182/blood-2002-05-1598 · Cited by 102 · see citing works

Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells

Lim, J. T. E., MANSUKHANI, M. M., & Weinstein, I. B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501203102 · Cited by 102 · see citing works

Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.

Chilosi, M., Doglioni, C., Yan, Z., Lestani, M., Menestrina, F., Sorio, C., Benedetti, A., Vinante, F., Pizzolo, G., & Inghirami, G. (1998) · Europe PMC (PubMed Central) · Cited by 96 · see citing works

Is Cyclin D1-CDK4 kinase a bona fide cancer target?

Malumbres, M., & Barbacid, M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.026 · Cited by 96 · see citing works

Beyond the cell cycle: A new role for Cdk6 in differentiation

Grossel, M. J., & Hinds, P. W. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20712 · Cited by 85 · see citing works

JunB inhibits proliferation and transformation in B-lymphoid cells

Szremska, A., Kenner, L., Weisz, E., Ott, R. G., Passegue, E. A., Artwohl, M., Freissmuth, M., Stoxreiter, R., Theussl, H., Parzer, S. B., et al. (2003) · Blood · doi:10.1182/blood-2003-03-0915 · Cited by 83 · see citing works

Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma

Nagel, S., Leich, E., Quentmeier, H., Meyer, C., Kaufmann, M., Drexler, H. G., Zettl, A., Rosenwald, A., & MacLeod, R. (2007) · Leukemia · doi:10.1038/sj.leu.2405028 · Cited by 77 · see citing works

Negative Regulation of TSC1-TSC2 by Mammalian D-Type Cyclins

Zacharek, S. J., Xiong, Y., & Shumway, S. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2236 · Cited by 72 · see citing works

Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family

Rodríguez‐Otero, P., Román‐Gómez, J., Vilas‐Zornoza, A., José‐Eneriz, E. S., Martín‐Palanco, V., Rifón, J., Torres, A., Calasanz, M. J., Agirre, X., & Prósper, F. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08812.x · Cited by 58 · see citing works

Genetic and environmental factors in cutaneous malignant melanoma

Paillerets, B. B., Avril, M., Chompret, A., & Démenais, F. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01360-8 · Cited by 57 · see citing works

cdk6 Can Shorten G1 Phase Dependent upon the N-terminal INK4 Interaction Domain

Grossel, M. J., Baker, G. L., & Hinds, P. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.29960 · Cited by 56 · see citing works

In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene

Hayette, S., Tigaud, I., Callet‐Bauchu, E., Ffrench, M., Gazzo, S., Wahbi, K., Callanan, M. B., Felman, P., Dumontet, C., Magaud, J., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1220 · Cited by 56 · see citing works

Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia.

Brito‐Babapulle, V., Gruszka, A., Platt, G., Andersen, C. L., Elnenaei, M. O., Matutes, E., Wotherspoon, A. C., Weston-Smith, S., & Catovsky, D. (2002) · PubMed · Cited by 47 · see citing works

JNK/AP-1 pathway is involved in tumor necrosis factor-α induced expression of vascular endothelial growth factor in MCF7 cells

Yin, Y., Wang, S., Sun, Y., Matt, Y., Colburn, N. H., Shu, Y., & Han, X. (2009) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2009.04.045 · Cited by 47 · see citing works

Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes.

Ericson, K. K., Krull, D., Slomiany, P., & Grossel, M. J. (2003) · PubMed · Cited by 45 · see citing works

Cyclin D3 Is a Cofactor of Retinoic Acid Receptors, Modulating Their Activity in the Presence of Cellular Retinoic Acid-binding Protein II

Despouy, G., Bastie, J.-N., Deshaies, S., Balitrand, N., Mazharian, A., Rochette‐Egly, C., Chomienne, C., & Delva, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210697200 · Cited by 45 · see citing works

c-JUN promotes BCR-ABL–induced lymphoid leukemia by inhibiting methylation of the 5′ region of Cdk6

Kollmann, K., Heller, G., Ott, R. G., Scheicher, R., Zebedin-Brandl, E. M., Schneckenleithner, C., Simma, O., Warsch, W., Eckelhart, E., Hoelbl‐Kovacic, A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-299644 · Cited by 38 · see citing works

Expression of Cyclin-Dependent Kinase 6 (cdk6) and Frequent Loss of CD44 in Nasal-Nasopharyngeal NK/T-Cell Lymphomas: Comparison with CD56-Negative Peripheral T-Cell Lymphomas

Lien, H., Lin, C.-W., Huang, P., Chang, M., & Hsu, S.-M. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780093 · Cited by 34 · see citing works

DNA methylation in haematological malignancies: the role of decitabine

Hennessy, B. T., Garcia‐Manero, G., Kantarjian, H. M., & Giles, F. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.12.1985 · Cited by 31 · see citing works

Vascular Endothelial Growth Factor Expression in Arthritic Joint Is Regulated by SAF-1 Transcription Factor

Ray, B. K., Shakya, A., & Ray, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1774 · Cited by 30 · see citing works

Clinicopathologic Features of CDK6 Translocation-associated B-cell Lymphoproliferative Disorders

Chen, D., Law, M. E., Theis, J. D., Gamez, J. D., Caron, L. B., Vrana, J. A., & Doǧan, A. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181934244 · Cited by 27 · see citing works

JunB is a gatekeeper for B-lymphoid leukemia

Ott, R. G., Simma, O., Kollmann, K., Weisz, E., Zebedin, E., Schorpp‐Kistner, M., Heller, G., Zöchbauer‐Müller, S., Wagner, E. F., Freissmuth, M., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210285 · Cited by 25 · see citing works

Cell Cycle-Based Therapies Move Forward

Malumbres, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.024 · Cited by 24 · see citing works

c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard

Kollmann, K., Heller, G., & Sexl, V. (2011) · Oncotarget · doi:10.18632/oncotarget.279 · Cited by 19 · see citing works

Novel germline CDK4 mutations in patients with head and neck cancer

Sabir, M., Baig, R. M., Mahjabeen, I., & Kayani, M. A. (2012) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-10-11 · Cited by 15 · see citing works

The silence of the genes: epigenetic disturbances in haematopoietic malignancies

Hackanson, B. W., Guo, Y., & Lübbert, M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.1.45 · Cited by 13 · see citing works

Sequencing of t(2;7) Translocations Reveals a Consistent Breakpoint Linking CDK6 to the IGK Locus in Indolent B-Cell Neoplasia

Parker, E. P. K., Siebert, R., Oo, T. H., Schneider, D., Hayette, S., & Wang, C. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.07.006 · Cited by 8 · see citing works

Cell cycle proteins as promising targets in cancer therapy

Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,875 · see citing works

Cyclin-dependent kinases

Malumbres, M. (2014) · Genome biology · doi:10.1186/gb4184 · Cited by 1,683 · see citing works

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · see citing works

Targeting cell-cycle machinery in cancer

Suski, J. M., Braun, M., Strmiska, V., & Siciński, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 566 · see citing works

Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases

Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528 · see citing works

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

Álvarez‐Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 395 · see citing works

Cell cycle on the crossroad of tumorigenesis and cancer therapy

Liu, J., Peng, Y., & Wei, W. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.001 · Cited by 381 · see citing works

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Pandey, K., An, H. J., Kim, S., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2018) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 366 · see citing works

Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments

Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 332 · see citing works

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 339 · see citing works

Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy

Yan, M., Wang, C., He, B., Yang, M., Tong, M., Long, Z., Liu, B., Peng, F., Xu, L., Zhang, Y., et al. (2016) · Medicinal Research Reviews · doi:10.1002/med.21399 · Cited by 296 · see citing works

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation

Scheicher, R., Hoelbl‐Kovacic, A., Bellutti, F., Tigan, A.-S., Prchal‐Murphy, M., Heller, G., Schneckenleithner, C., Salazar‐Roa, M., Zöchbauer‐Müller, S., Zuber, J. A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-584417 · Cited by 263 · see citing works

Development of dual and selective degraders of cyclin-dependent kinases 4 and 6

Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272 · see citing works

Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML

Brand, M., Jiang, B., Bauer, S., Donovan, K. A., Liang, Y., Wang, E. S., Nowak, R. P., Yuan, J. C., Zhang, T., Kwiatkowski, N., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.006 · Cited by 258 · see citing works

Cyclin D-CDK4/6 functions in cancer

Gao, X., Leone, G. W., & Wang, H. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.02.002 · Cited by 220 · see citing works

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies

Kennedy, V. E., & Smith, C. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.612880 · Cited by 206 · see citing works

CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation

Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204 · see citing works

Rethink of EGFR in Cancer With Its Kinase Independent Function on Board

Thomas, R., & Weihua, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00800 · Cited by 204 · see citing works

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

Sánchez-Martínez, C., Lallena, M. J., Sanfeliciano, S. G., & de Dios, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126637 · Cited by 200 · see citing works

The role of CDK6 in cancer

Nebenfuehr, S., Kollmann, K., & Sexl, V. (2020) · International Journal of Cancer · doi:10.1002/ijc.33054 · Cited by 185 · see citing works

Structural Basis for the Non-catalytic Functions of Protein Kinases

Kung, J. E., & Jura, N. (2016) · Structure · doi:10.1016/j.str.2015.10.020 · Cited by 176 · see citing works

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558114 · Cited by 170 · see citing works

Immunomodulation by anticancer cell cycle inhibitors

Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163 · see citing works

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

Li, Q., Jiang, B., Guo, J., Shao, H., Priore, I. S. D., Chang, Q., Kudo, R., Li, Z., Razavi, P., Liu, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1726 · Cited by 167 · see citing works

Targeting CDK6 in cancer: State of the art and new insights

Tadesse, S., Yu, M., Kumarasiri, M., Le, B. T., & Wang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1084445 · Cited by 166 · see citing works

Targeted protein degradation: current and future challenges

Hanzl, A., & Winter, G. E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.012 · Cited by 154 · see citing works

Senescence as a therapeutically relevant response to CDK4/6 inhibitors

Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148 · see citing works

CK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy

Cai, J., Li, R., Xu, X., Zhang, L., Lian, R., Fang, L., Huang, Y., Feng, X., Liu, X., Xu, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0065-8 · Cited by 145 · see citing works

Cyclin-Dependent Kinase 6 Is a Chromatin-Bound Cofactor for NF-κB-Dependent Gene Expression

Handschick, K., Beuerlein, K., Jurida, L., Bartkuhn, M., Müller, H., Soelch, J., Weber, A., Dittrich-Breiholz, O., Schneider, H., Scharfe, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.002 · Cited by 141 · see citing works

Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders

Steinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc00167h · Cited by 148 · see citing works

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6

Uras, I. Z., Walter, G. J., Scheicher, R., Bellutti, F., Prchal‐Murphy, M., Tigan, A.-S., Valent, P., Heidel, F. H., Kubicek, S., Scholl, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683581 · Cited by 138 · see citing works

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)

Huang, J., Zheng, L., Sun, Z., & Li, J. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5184 · Cited by 141 · see citing works

The Role of CDK4/6 Inhibition in Breast Cancer

Murphy, C. G., & Dickler, M. N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0443 · Cited by 138 · see citing works

Selective degradation of CDK6 by a palbociclib based PROTAC

Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic &amp; Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135 · see citing works

Acquired resistance in cancer: towards targeted therapeutic strategies

Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 145 · see citing works

Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor

Clark, A. S., Karasic, T. B., DeMichele, A. M., Vaughn, D. J., O’Hara, M. H., Perini, R. F., Zhang, P. J., Lal, P., Feldman, M. D., Gallagher, M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4701 · Cited by 131 · see citing works

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 126 · see citing works

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126 · see citing works

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

Adkins, D. R., Ley, J. C., Neupane, P. C., Worden, F. P., Sacco, A. G., Palka, K. A., Grilley‐Olson, J. E., Maggiore, R. J., Salama, N. N., Trinkaus, K. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30405-x · Cited by 123 · see citing works

Targeting cell cycle regulators in hematologic malignancies

Aleem, E. A., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 122 · see citing works

Transcriptomic characterization of fibrolamellar hepatocellular carcinoma

Simon, E. P., Freije, C. A., Farber, B. A., Lalazar, G., Darcy, D. G., Honeyman, J. N., Chiaroni-Clarke, R. C., Dill, B. D., Molina, H., Bhanot, U. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424894112 · Cited by 115 · see citing works

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer

Chou, A. S. Y., Froio, D., Nagrial, A. M., Parkin, A., Murphy, K. J., Chin, V. T., Wohl, D., Steinmann, A. M., Stark, R., Drury, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-315144 · Cited by 117 · see citing works

Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib

Poratti, M., & Marzaro, G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.064 · Cited by 115 · see citing works

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer

Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07258-y · Cited by 103 · see citing works

Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression

Schmitz, M. L., & Kracht, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.004 · Cited by 95 · see citing works

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

De Dominici, M., Porazzi, P., Xiao, Y., Chao, A., Tang, H.-Y., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L. F., et al. (2020) · Blood · doi:10.1182/blood.2019003604 · Cited by 94 · see citing works

Crossing the LINE Toward Genomic Instability: LINE-1 Retrotransposition in Cancer

Kemp, J. R., & Longworth, M. S. (2015) · Frontiers in Chemistry · doi:10.3389/fchem.2015.00068 · Cited by 91 · see citing works

CDK4: a master regulator of the cell cycle and its role in cancer

Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 84 · see citing works

CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation

Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 79 · see citing works

Role of angiogenesis in melanoma progression: Update on key angiogenic mechanisms and other associated components

Cho, W. C., Jour, G., & Aung, P. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.015 · Cited by 83 · see citing works

Recent Advances in PROTACs for Drug Targeted Protein Research

Yao, T., Xiao, H., Wang, H., & Xu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810328 · Cited by 78 · see citing works

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Palmer, C. L., Boras, B. W., Pascual, B., Li, N., Li, D., Garza, S. J., Huser, N. H., Yuan, J. T., Cianfrogna, J. A., Sung, T., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.006 · Cited by 79 · see citing works

CDK6 Antagonizes p53-Induced Responses during Tumorigenesis

Bellutti, F., Tigan, A.-S., Nebenfuehr, S., Dolezal, M., Zojer, M., Grausenburger, R., Hartenberger, S., Kollmann, S., Doma, E., Prchal‐Murphy, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0912 · Cited by 75 · see citing works

NK cells in hypoxic skin mediate a trade-off between wound healing and antibacterial defence

Sobecki, M., Krzywińska, E., Nagarajan, S., Audigé, A., Huỳnh, K., Zacharjasz, J., Debbache, J., Kerdiles, Y. M., Gotthardt, D., Takeda, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25065-w · Cited by 75 · see citing works

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Schmoellerl, J., Barbosa, I. A. M., Eder, T., Brandstoetter, T., Schmidt, L., Maurer, B., Troester, S., Pham, H. T. T., Mohanty, S., Ebner, J., et al. (2020) · Blood · doi:10.1182/blood.2019003267 · Cited by 74 · see citing works

Therapeutic targeting of replicative immortality

Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 74 · see citing works

miR-365 Promotes Cutaneous Squamous Cell Carcinoma (CSCC) through Targeting Nuclear Factor I/B (NFIB)

Zhou, M., Zhou, L., Li, Z., Guo, L., Wang, Y., Liu, H., Ou, C., & Ding, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100620 · Cited by 73 · see citing works

miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3

Zhang, Y., Huang, W. M., Ran, Y., Xiong, Y., Zhong, Z., Fan, X., Wang, Z., & Ye, Q. (2015) · Tumor Biology · doi:10.1007/s13277-015-3582-0 · Cited by 73 · see citing works

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

Chen, E. X., Hotte, S. J., Hirte, H. W., Siu, L. L., Lyons, J., Squires, M. S., Lovell, S., Turner, S., McIntosh, L., & Seymour, L. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.565 · Cited by 72 · see citing works

Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions

Fu, D., & Wang, T. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01485-7 · Cited by 70 · see citing works

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer

Alves, C. L., Eliáš, D., Lyng, M., Bak, M., Kirkegaard, T., Lykkesfeldt, A. E., & Ditzel, H. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1984 · Cited by 69 · see citing works

Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs

Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic &amp; Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127106 · Cited by 69 · see citing works

A kinase-independent role for CDK8 in BCR-ABL1+ leukemia

Menzl, I., Zhang, T., Berger‐Becvar, A., Grausenburger, R., Heller, G., Prchal‐Murphy, M., Edlinger, L., Knab, V. M., Uras, I. Z., Grundschober, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12656-x · Cited by 68 · see citing works

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma

Ng, Y. L. D., Ramberger, E., Bohl, S., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28515-1 · Cited by 68 · see citing works

CDK6 Inhibition: A Novel Approach in AML Management

Uras, I. Z., Sexl, V., & Kollmann, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072528 · Cited by 65 · see citing works

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation

Kollmann, K., Warsch, W., Arias, C. G., Nice, F. L., Avezov, E., Milburn, J. V., Li, J., Dimitropoulou, D., Biddie, S. C., Wang, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.280 · Cited by 62 · see citing works

CBX3 promotes colon cancer cell proliferation by CDK6 kinase-independent function during cell cycle

Fan, Y., Li, H., Liang, X., & Xiang, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.15253 · Cited by 62 · see citing works

Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6

Cao, J., Zhang, Y., Mu, J., Yang, D., Gu, X., & Zhang, J. (2021) · Human Cell · doi:10.1007/s13577-021-00522-2 · Cited by 61 · see citing works

Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability

Ge, X., Frank-Bertoncelj, M., Klein, K., McGovern, A., Kuret, T., Houtman, M., Burja, B., Micheroli, R., Shi, C., Marks, M., et al. (2020) · Genome Biology · doi:10.1186/s13059-021-02460-6 · Cited by 52 · see citing works

The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis

Müller, A., Dickmanns, A., Resch, C., Schäkel, K., Hailfinger, S., Dobbelstein, M., Schulze‐Osthoff, K., & Kramer, D. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134217 · Cited by 60 · see citing works

The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer

Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 60 · see citing works

Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells

Singh, L., Aldossary, S. A., Saeedan, A. S., Ansari, M. N., & Kaithwas, G. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.016 · Cited by 59 · see citing works

Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma

Leung, C. O. N., Yang, Y., Leung, R. W. H., So, K. K. H., Guo, H. J., Lei, M. M. L., Muliawan, G. K., Gao, Y., Yu, Q. Q., Yun, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42360-w · Cited by 58 · see citing works

Human CDK18 promotes replication stress signaling and genome stability

Barone, G., Staples, C. J., Ganesh, A., Patterson, K. W., Bryne, D. P., Myers, K. N., Patil, A. A., Eyers, C. E., Maslen, S., Skehel, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw615 · Cited by 59 · see citing works

Progress with palbociclib in breast cancer: latest evidence and clinical considerations

Rocca, A., Schirone, A., Maltoni, R., Bravaccini, S., Cecconetto, L., Farolfi, A., Bronte, G., & Andreis, D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016677961 · Cited by 59 · see citing works

Biomedical application of Indole-3-carbinol: A mini-review

Singh, A. A., Patil, M. P., Kang, M., Niyonizigiye, I., & Kim, G. (2020) · Phytochemistry Letters · doi:10.1016/j.phytol.2020.09.024 · Cited by 56 · see citing works

The interplay of CDK4 and CDK6 in melanoma

Kollmann, K., Briand, C., Bellutti, F., Schicher, N., Blunder, S., Zojer, M., & Höeller, C. (2019) · Oncotarget · doi:10.18632/oncotarget.26515 · Cited by 55 · see citing works

Targeting Protein Kinases Degradation by PROTACs

Yu, F., Cai, M., Shao, L., & Zhang, J. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.679120 · Cited by 54 · see citing works

Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways

Dai, M., Boudreault, J., Wang, N., Poulet, S., Daliah, G., Yan, G., Moamer, A., Burgos, S. A., Sabri, S., Ali, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2121 · Cited by 53 · see citing works

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Wang, Z., Huang, W., Zhou, K., Ren, X., & Ding, K. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01978 · Cited by 52 · see citing works

The application and research progress of anti-angiogenesis therapy in tumor immunotherapy

Tu, J., Liang, H., Li, C., Huang, Y., Wang, Z., Chen, X., & Yuan, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198972 · Cited by 53 · see citing works

Panax notoginseng saponins attenuate lung cancer growth in part through modulating the level of Met/miR-222 axis

Yang, Q., Wang, P., Cui, J., Wang, W., Chen, Y., & Zhang, T. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.08.040 · Cited by 52 · see citing works

NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies

Kokuryo, T., Yokoyama, Y., Yamaguchi, J., Tsunoda, N., Ebata, T., & Nagino, M. (2019) · Anticancer Research · doi:10.21873/anticanres.13341 · Cited by 51 · see citing works

A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification

Zhang, J., Liu, X., Zhou, W., Cheng, G., Wu, J., Guo, S., Jia, S., Liu, Y., Li, B., Zhang, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68224-7 · Cited by 51 · see citing works

miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells

Hoareau‐Aveilla, C., Quelen, C., Congras, A., Caillet, N., Labourdette, D., Dozier, C., Brousset, P., Lamant, L., & Meggetto, F. (2018) · Haematologica · doi:10.3324/haematol.2018.195131 · Cited by 49 · see citing works

MiR-644a Disrupts Oncogenic Transformation and Warburg Effect by Direct Modulation of Multiple Genes of Tumor-Promoting Pathways

Ebron, J. S., Shankar, E., Singh, J., Sikand, K., Weyman, C. M., Gupta, S., Lindner, D. J., Liu, X., Campbell, M. J., & Shukla, G. C. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2993 · Cited by 49 · see citing works

H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma.

Li, C., Lei, B., Huang, S., Zheng, M., Liu, Z., Li, Z., & Deng, Y. (2015) · Europe PMC (PubMed Central) · Cited by 48 · see citing works

CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment

Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 47 · see citing works

Targeting CDK4/6 for Anticancer Therapy

Qi, J., & Ouyang, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030685 · Cited by 48 · see citing works

The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia

Zhang, J., Zhou, L., Zhao, S., Dicker, D. T., & El‐Deiry, W. S. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1320005 · Cited by 47 · see citing works

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27

Pennycook, B. R., & Barr, A. R. (2021) · Open Biology · doi:10.1098/rsob.210125 · Cited by 43 · see citing works

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system

Maurer, B., Brandstoetter, T., Kollmann, S., Sexl, V., & Prchal‐Murphy, M. (2020) · Haematologica · doi:10.3324/haematol.2020.256313 · Cited by 46 · see citing works

miR-124-3p is a chronic regulator of gene expression after brain injury

Vuokila, N., Łukasiuk, K., Bot, A. M., van Vliet, E. A., Aronica, E., Pitkänen, A., & Puhakka, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2911-z · Cited by 45 · see citing works

CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks

Uras, I. Z., Maurer, B., Nivarthi, H., Jodl, P., Kollmann, K., Prchal‐Murphy, M., Feenstra, J. D. M., Zojer, M., Lagger, S., Grausenburger, R., et al. (2019) · Blood · doi:10.1182/blood-2018-08-872648 · Cited by 46 · see citing works

The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance

Abdelmalak, M., Singh, R., Anwer, M. I., Ivanchenko, P., Randhawa, A., Ahmed, M., Ashton, A. W., Du, Y., Jiao, X., & Pestell, R. G. (2022) · Cancers · doi:10.3390/cancers14215388 · Cited by 45 · see citing works

Cyclin‐dependent kinases: Masters of the eukaryotic universe

Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 45 · see citing works

MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells

Mazzoccoli, L., Robaina, M. C., Apa, A. G., Bonamino, M., Pinto, L. W., Queiroga, E., Bacchi, C. E., & Klumb, C. E. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2575-3 · Cited by 45 · see citing works

Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors

Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 44 · see citing works

Development of CDK4/6 Inhibitors: A Five Years Update

Ammazzalorso, A., Agamennone, M., Filippis, B. D., & Fantacuzzi, M. (2021) · Molecules · doi:10.3390/molecules26051488 · Cited by 43 · see citing works

The Kinase-Independent, Second Life of CDK6 in Transcription

Otto, T., & Siciński, P. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.019 · Cited by 25 · see citing works

Branching Out

Ferrarelli, L. K. (2013) · Science Signaling · doi:10.1126/scisignal.2004690

CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis

Sexl, V., Kollmann, K., & Bellutti, F. (2019) · Blood · doi:10.1182/blood-2019-121101 · Cited by 1 · see citing works

Targeting CDK6 in cancer: State of the art and new insights

Tadesse, S., Yu, M., Kumarasiri, M., Le, B. T., & Wang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1084445 · Cited by 166 · see citing works

CDK6 and p16INK4A in lymphoid malignancies

Kollmann, K., & Sexl, V. (2013) · Oncotarget · doi:10.18632/oncotarget.1541 · Cited by 32 · see citing works